EMA guidelines

    The most part of this information is from EMA website. This part is a transcription of the information available in EMA website. “This page lists the European Medicines Agency’s scientific guidance documents on biosimilar medicines. Due to the fact that there are is a lot of documentation, we are going to divide the guidelines in […]

    The most part of this information is from EMA website. This part is a transcription of the information available in EMA website.

    “This page lists the European Medicines Agency’s scientific guidance documents on biosimilar medicines.

    Due to the fact that there are is a lot of documentation, we are going to divide the guidelines in 3 posts:

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

More on Curaxys
We focus on the research, production and commercialization of recombinant proteins added value through the utilization of CuraMab® with specific human cell lines
Our expression system allows us to reach of recombinant protein levels that are clearly above those currently available.
We developed a downstream technological platform on the basis of our own laboratory data.

More articles

  • Curaxys obtains financing for the purchase of equipment with the help granted by Innplanta 2012
  • Curaxys hires five more technologists.
  • One of the largest biopharmaceutical projects in Europe to be started at Tecnobahía.
  • Innovaxis, a novel company for “custom medicine”
  • Strategic Alliance for cancer disease
  • UCA and Curaxys create a Cathedra in biopharmaceuticals in order to research biosimilar proteins
  • Curaxys is ranked among the world top ten companies in the research of biologic generic medicines

  • Copyright 2012 Curaxys. All Rights Reserved
    Legal Advice